Research Brief
Tirzepatide: Chemical Properties
13 PubMed CitationsExpert ReviewedGMP CertifiedLast Reviewed: May 2026
Chemical Properties
| Formula | C164H252N44O55S |
| Molecular Weight | 3752.1 Da |
| Synonyms | Teduglutide, GLP-2 Analog, ALX-0600, Gattex, Revestive |
| Cas Number | 197922-42-2 |
| Sequence | His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp |
| Pubchem Cid | 16133828 |
| Monoisotopic Mass | N/A |
| Polar Area | N/A |
| Complexity | N/A |
| X Log P | N/A |
| Heavy Atom Count | N/A |
| H Bond Donor Count | N/A |
| H Bond Acceptor Count | N/A |
| Rotatable Bond Count | N/A |
Identifiers
| Pubchem Cid | 16133828 |
| Inchi Key | N/A |
| Inchi | N/A — 33-amino acid linear peptide |
| Smiles Isomeric | N/A — 33-AA peptide (full SMILES via PubChem CID 16133828) |
| Smiles Canonical | N/A — 33-AA peptide (full SMILES via PubChem CID 16133828) |
| Iupac Name | Teduglutide — 33-amino acid GLP-2 analog peptide with Gly2→Ala substitution |
References
- Drucker DJ, et al. (1996). Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol, 15(7):673–677.
- Drucker DJ, Yusta B. (2014). Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol, 76:561–583.
- FDA. (2012). NDA 203441 Approval Letter — Gattex (teduglutide) for injection. U.S. Food and Drug Administration.
- Drucker DJ, et al. (1996). Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA, 93(15):7911–7916.
- Jeppesen PB, et al. (2012). Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology, 143(6):1473–1481.
- Leen JLS, et al. (2011). Mechanism of action of glucagon-like peptide 2 to increase IGF-I mRNA in intestinal subepithelial fibroblasts. Endocrinology, 152(2):436–446.
- Jeppesen PB, et al. (2005). Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut, 54(9):1224–1231.
- Gattex (teduglutide) Prescribing Information. (2019). Takeda Pharmaceuticals USA, Inc.
- Schwartz LK, et al. (2016). Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome. Clin Transl Gastroenterol, 7(2):e142.
- Jeppesen PB, et al. (2018). Factors associated with response to teduglutide in patients with short-bowel syndrome and intestinal failure. Gastroenterology, 154(4):874–885.
- Kocoshis SA, et al. (2020). Safety and efficacy of teduglutide in pediatric patients with short bowel syndrome—intestinal failure. J Pediatr Gastroenterol Nutr, 70(4):521–528.
- Hukkinen M, et al. (2019). Parenteral nutrition-associated cholestasis and its association with teduglutide treatment in neonatal short bowel syndrome. J Pediatr Surg, 54(11):2281–2287.
- Drucker DJ, et al. (1999). Glucagon-like peptide 2 reduces intestinal permeability. Am J Physiol, 276(6):G1420–G1426.
Related Research Questions
FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.